-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Oppenheimer Adjusts Pliant Therapeutics' Price Target to $44 From $43, Maintains Outperform Rating

Oppenheimer Adjusts Pliant Therapeutics' Price Target to $44 From $43, Maintains Outperform Rating

MT Newswires · 03/10/2023 03:31